\
&
Contact us
\
&
Contact us
Published on | 1 year ago
ProgrammesThe European Innovation Council (EIC) selected 71 cutting edge companies for funding, combining grants and equity, following the last 2024 EIC Accelerator cut-off in October. They have been selected among 1211 submitted proposals, out of which 431 have been invited to the jury interviews.
21% of the selected companies are led by women (as CEO, CSO or CTO), while there is a geographical spread spanning 16 countries.
Four of the selected companies have benefitted from the ‘Plug In’ scheme. The scheme allows funding bodies managing certified national/regional programmes to submit projects from their portfolio directly to the full application stage of the EIC Accelerator.
A further 330 applications that were assessed positively by the EIC jury, but for which there was insufficient funding available, will be awarded a Seal of Excellence. This recognition helps these companies to find alternative funding sources, including from the Recovery and Resilience Funds and European Regional Development Funds.
3 Belgian organisations will receive blended financing.
More details available here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
